Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announced the completion of a GMP production run of its 5mg psilocybin finished drug product. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression, with additional product from the production run designated for upcoming clinical research in the United States and clinical trials in Europe.
The company said all stages of manufacturing were completed in-house at its Health Canada-licensed facility, including biomass cultivation, active pharmaceutical ingredient extraction, encapsulation and packaging. Optimi said its vertically integrated platform and commercial-scale production capacity position the company to supply finished psilocybin and MDMA drug products to regulated markets internationally for both patient access programs and clinical research initiatives.
This achievement underscores Optimi's ability to produce GMP-grade psychedelic drug products at scale, a critical step in meeting the growing demand for regulated psychedelic therapies. The completion of this production run is significant for the industry, as it demonstrates the feasibility of manufacturing consistent, high-quality psilocybin capsules that meet regulatory standards. For patients, this means increased access to potentially life-changing treatments for mental health conditions like treatment-resistant depression. For the industry, it validates the commercial viability of psychedelic pharmaceuticals and may encourage further investment and clinical development.
Optimi's vertically integrated operations, from biomass cultivation to final packaging, reduce reliance on third-party suppliers and ensure quality control throughout the manufacturing process. This positions the company to serve as a reliable supplier for clinical trials in the U.S. and Europe, where regulatory pathways for psychedelic therapies are evolving. The product designated for clinical research could contribute to the growing body of evidence supporting psilocybin's efficacy, potentially accelerating regulatory approvals and market expansion.
The announcement also highlights the global reach of Optimi's operations. The company's products are currently prescribed to patients in Australia under the Authorized Prescriber Scheme and are accessible in Canada through the Special Access Program. By supplying finished drug products to multiple regulated markets, Optimi is helping to build the infrastructure needed for widespread adoption of psychedelic therapies.
For investors, this news reinforces Optimi's position as a leading manufacturer in the psychedelic pharmaceutical sector. The company's ability to execute a GMP production run and supply commercial-grade product positions it for potential revenue growth as more countries develop regulatory frameworks for psychedelic therapies. The full press release is available at https://ibn.fm/Rx3ky.
Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. For more information, visit www.optimihealth.ca or optimi.net.
